Previous 10 | Next 10 |
EWING, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2019 financial results and recent operating progress before the market opens on Tuesday, November 5, 2019. Management will host a webcast and conference...
EWING, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from two poster presentations will be presented on Saturday October 26, 2019 at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA). ...
The share price action of Antares Pharma, Inc. ( ATRS ) (Medical Instruments & Supplies Firm) since late April definitely brings opportunities to the table for short-term traders. As we can see from the daily chart below, price came down to hit that supporting trend-line 4 if not 5 times b...
EWING, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 12:00 p.m. Eastern Time. A ...
Teva Pharmaceutical Industries (NYSE: TEVA ) announces the U.S. commercial launch of its generic version of Mylan's (NASDAQ: MYL ) emergency allergic reaction med EpiPen Jr (epinephrine injection, USP) Auto-Injector, 0.15 mg. More news on: Teva Pharmaceutical Industries Limited, Mylan N....
Antares Pharma, Inc. (ATRS) Q2 2019 Earnings Conference Call August 06, 2019 8:30 AM ET Company Participants Jack Howarth - Vice President of Corporate Affairs Bob Apple - President & Chief Executive Officer Fred Powell - Executive Vice President & Chief Financial Officer...
The following slide deck was published by Antares Pharma, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue The Company Increases Full Year 2019 Revenue Guidance to a Range of $100.0 to $110.0 Million EWING, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company...
EWING, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2019 financial results and recent operating progress before the market opens on Tuesday, August 6, 2019. Management will host a webcast and conference call a...
Introduction Antares Pharmaceuticals ( ATRS ) is a developer of intramuscular and subcutaneous injection devices including the VIBEX and VIBEXQuickShot pressure-assisted delivery systems. The company possesses several promising candidates in its pipeline; performed an impressive XYOSTED laun...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...